Drug-Resistant Empyema in Paediatrics - Recent Update (2024-2026)

Overview and Definition

1. Antibiotic-resistant pathogens causing empyema (MRSA, penicillin-non-susceptible pneumococcus, MDR Gram-negatives)
2. Treatment-refractory empyema requiring escalation beyond standard antibiotic + drainage

Current Microbiology and Resistance Patterns

Streptococcus pneumoniae (leading cause)

• Serotype 3 emerged as the dominant post-2021 strain and is strongly associated with empyema and necrotizing parenchyma (p < 0.001)
• Penicillin susceptibility (MIC ≤2 µg/mL) remained very high at 94% of isolates
• All 11 penicillin-resistant isolates (MIC >2 µg/mL) were serotype 19A - a PCV13-included serotype whose prevalence should decline with ongoing vaccine use
• PCV15 and PCV20 cover additional serotypes (22F, 33F, 8, 10A, 11A, 12F, 15B) contributing 22% of current isolates - newer vaccines may further reduce pneumococcal empyema

Clinical implication: Penicillin/amoxicillin resistance in pneumococcal empyema is NOT common overall. Serotype 19A is the key resistant strain; high-dose amoxicillin/beta-lactam is still appropriate first-line therapy in most cases in vaccinated populations.

Staphylococcus aureus (most dangerous resistant pathogen)

• S. aureus was identified in 38/1402 children with parapneumonic effusion/empyema
• MRSA accounted for 31.3% (10/32) of S. aureus isolates tested for susceptibility - this is the highest drug-resistance burden
• Penicillin resistance in S. pneumoniae was only 4.8% (3/63)

Diagnostic Advances for Rapid Resistance Detection

• Positive percent agreement for pleural specimens: 93.8% vs. standard culture
• Negative percent agreement: 99.6%
• Directly identifies antimicrobial resistance genes (mecA/MRSA, vanA/B, etc.) within hours vs. 48-72 hr for culture
• Strongest performance for S. pneumoniae (PPA 95.2%)
• Culture-negative cases - where empiric antibiotics have already been given - benefited most

• Post-PCR implementation: pathogen detection rate 73.4% vs 38.9% pre-PCR (p < 0.001)
• Time to optimal antibiotic therapy shortened from 10 days to 4.9 days (p < 0.001)
• MRSA therapy discontinuation occurred earlier: 1.5 vs 2.5 days (p = 0.03)

Antibiotic Management by Pathogen/Resistance

Empiric Therapy

• Most common empiric agents: cefuroxime (51% monotherapy) and aminopenicillin/BLI (24%)
• Common additions: macrolides, aminoglycosides, clindamycin
• No difference in clinical outcomes between cefuroxime and amoxicillin-clavulanate empirically

MRSA-Specific Regimens (Red Book 2021 / textbook guidance)

• Source: Red Book 2021 [ISBN 9781610025218], Murray & Nadel's Textbook of Respiratory Medicine
• Vancomycin monotherapy for MRSA pneumonia complicating influenza is associated with higher mortality - combination therapy mandatory

MDR Gram-Negatives and Hospital-Acquired Empyema

• Piperacillin-tazobactam - standard for beta-lactam-resistant Staphylococci and Gram-negatives; note: pediatric pharmacokinetics differ from adults with higher clearance rates, suggesting more frequent dosing
• Meropenem ± fosfomycin IV for confirmed MDR Gram-negatives or carbapenem-susceptible organisms
• Meropenem/fosfomycin combination has shown benefit for Pseudomonas aeruginosa and other MDR pathogens in severe pediatric pneumonia

Antibiotic Stewardship in Empyema

Drainage and Procedural Management

• In 141 children with empyema, 76% underwent chest tube + fibrinolytic
• Delayed fibrinolytic (≥24h after chest tube) doubled the rate of repeat procedures: 46.5% vs 15.6% (p = 0.0005)
• Timely fibrinolytic administration is critical - integrate as pathway requirement at time of chest tube placement
• Health disparities identified: non-English-speaking families had longer LOS; race/ethnicity differences in repeat procedure rates

Summary Algorithm for Drug-Resistant Paediatric Empyema

EMPYEMA CONFIRMED (imaging + pleural fluid analysis)
│
├── RAPID DIAGNOSTICS (Day 0-1):
│   ├── Pleural fluid: culture, Gram stain, PCR (S. pneumoniae, MRSA)
│   ├── Blood culture
│   ├── Consider syndromic panel (BioFire JI Panel) if available
│   └── MRSA screening (nares/skin)
│
├── EMPIRIC ANTIBIOTICS:
│   ├── Community-acquired, vaccinated: Amoxicillin-clavulanate OR Cefuroxime
│   ├── + Cover MRSA if: severe disease, necrotizing features, influenza co-infection,
│   │   healthcare contact → Add Vancomycin (+ Clindamycin/Linezolid if influenza present)
│   └── Hospital-acquired/MDR risk: Pip-Taz OR Meropenem
│
├── DRAINAGE (concurrent):
│   ├── Chest tube + EARLY intrapleural fibrinolytic (tPA ± DNAse) → preferred
│   ├── VATS if fibrinolytic fails or complex loculated empyema
│   └── Decortication for late organizing empyema
│
├── DE-ESCALATE based on:
│   ├── PCR/culture results → narrow to organism-specific therapy
│   ├── MRSA negative → discontinue vancomycin promptly
│   └── Clinical improvement + drainage clearing
│
└── DURATION: Typically 2-4 weeks IV/oral depending on pathogen, drainage adequacy

Emerging and Special Situations

• Mycoplasma hominis empyema post-lung transplant [PMID 41147060]: rare, requires macrolides or doxycycline; inherently resistant to beta-lactams
• COVID-19 impact: Pneumococcal empyema fell sharply in 2020, surged 2022-2023 with serotype 3 predominance; post-COVID immune debt has altered epidemiology
• Necrotizing pneumonia with empyema: High association with S. aureus (especially CA-MRSA) and serotype 3 pneumococcus; requires prolonged antibiotics (4-6 weeks) and higher surgical intervention rates
• Post-COVID serotype shift: Serotype 3 (not covered by newer PCV vaccines for direct protection due to poor conjugation) is now the leading cause of severe pediatric pneumococcal empyema

Key References

1. Engstrom et al. Pneumococcal Pneumonia in Hospitalized Children 2017-2023. Pediatrics, 2026 - [PMID 42036116] - serotype 3, penicillin resistance data
2. Fernandez et al. Conservative and Surgical Modalities for Pediatric Empyema. Chest, 2023 - [PMID 37463660] - living network meta-analysis
3. Tzoni et al. Management of Complicated Pneumonia in Children. J Pediatr Surg, 2026 - [PMID 41109518] - surgical vs non-surgical systematic review
4. Forster et al. Empiric Antibiotic Therapy in 1402 Children with PPE/PE. Pediatr Infect Dis J, 2024 - [PMID 38713819] - MRSA 31%, antibiotic overtreatment
5. Ho et al. Pleural Fluid S. pneumoniae PCR Testing. Clin Infect Dis, 2024 - [PMID 39207213] - molecular diagnostics impact
6. Sanchez et al. Syndromic Panel for Pediatric Pleural Infections. J Clin Microbiol, 2025 - [PMID 40892445] - BioFire JI Panel performance
7. Spurr et al. Clinical Pathway Impact on Pediatric Empyema. Pediatr Pulmonol, 2026 - [PMID 41608991] - delayed fibrinolytic harms
8. Red Book 2021 - MRSA treatment guidelines, vancomycin combination therapy for influenza-MRSA

Culture-Negative Empyema in Paediatrics: Why No Growth Occurs and What to Do

Why Cultures Are Negative - The Core Problem

• Blood culture positivity in CAP-complicated empyema: < 20% overall
• Pleural fluid culture positivity: only 24% in children, even in frank empyema
• In the MATE study (100 children, Melbourne 2019-2023), 76 out of 100 children had negative cultures [PMID 38917227]

Reasons for No Growth (Stepwise)

1. Prior Antibiotic Exposure (Most Common Cause)

• Nearly all children with empyema have received antibiotics before pleural drainage - often for days
• Antibiotics sterilise the fluid and kill or inhibit bacterial growth in culture
• Prior antibiotic treatment is the single most important cause of false-negative cultures in paediatric empyema
• Murray & Nadel's Textbook confirms: "Prior antibiotic treatment decreases the yield of blood cultures" - the same applies even more powerfully to pleural fluid
• The organisms' DNA and antigens remain detectable even when bacteria are no longer viable/culturable

2. Low Bacterial Density in Pleural Fluid

• Pleural space is not the primary site of infection - it is a secondary, reactive process
• Bacterial load in pleural fluid is often very low
• Sensitivity of conventional culture is inherently poor even without antibiotics

3. Fastidious and Non-Standard Organisms

4. Transport and Processing Delays

• Pleural fluid left at room temperature - bacteria die
• Samples not inoculated into blood culture bottles (which have optimal growth media) lose viability rapidly

What Culture Negativity Does NOT Mean

• It does NOT mean "no bacteria present"
• It does NOT mean antibiotics should be stopped
• It does NOT mean the empyema is "sterile" or viral
• It does NOT indicate drug resistance

Modern Diagnostics to Overcome Culture-Negative Results

1. Pleural Fluid PCR (Now the Standard of Care)

• Culture detected pathogen in only 24/100 children
• PCR detected pathogen in 90/100 children (90%) (p < 0.001)
• PCR rescued a diagnosis in 68/76 (90%) culture-negative specimens
• S. pneumoniae was found in 67% of children - virtually all by PCR, missed by culture
• PCR would have reduced untargeted antibiotic duration by a median 20 days in 61% of cases

• Culture identified pathogens in only 29.7% of children
• PCR identified additional pathogens in 31.1% more
• 23 out of 29 pneumococcal diagnoses (79%) were by PCR only - completely missed by culture
• Serotype 3 accounted for 63% of pneumococcal empyema - and most were in fully vaccinated children

2. BinaxNOW Pneumococcal Antigen in Pleural Fluid (2026 Data)

Caveat: In children, urine BinaxNOW and nasopharyngeal carriage can give false positives - but pleural fluid BinaxNOW is highly specific.

3. Syndromic PCR Panels (BioFire Joint Infection Panel)

• PPA 93.8% for pleural specimens vs. standard care
• NPA 99.6%
• Also detects resistance genes (mecA for MRSA, vanA/B) directly in 1-2 hours
• Especially valuable in culture-negative cases where empiric broad-spectrum antibiotics have already been given [PMID 40892445]

4. Serological and Antigen Tests for Atypicals

• Mycoplasma IgM/IgG
• ASO titre (Group A Strep)
• Pneumococcal urinary antigen (less specific in children due to carriage)
• Legionella urinary antigen (rare in children but consider in atypical/severe)

Management When Cultures Are Negative

Do NOT stop antibiotics or consider treatment failure

Step 1: Send pleural fluid IMMEDIATELY for:
  ✓ Multiplex PCR (S. pneumoniae, GAS, S. aureus, H. influenzae)
  ✓ BinaxNOW antigen test on pleural fluid (if available)
  ✓ Anaerobic culture (proper transport media)
  ✓ Mycoplasma serology
  ✓ Inoculate into blood culture bottles (higher yield than plain culture)

Step 2: Continue empiric antibiotic cover
  ✓ Community-acquired, vaccinated: Continue amoxicillin-clavulanate or cefuroxime
  ✓ No improvement at 48-72h: Add MRSA cover (vancomycin)
  ✓ Suspected atypicals (older child, bilateral, subacute): Add azithromycin

Step 3: If PCR/antigen positive for pneumococcus:
  ✓ De-escalate to high-dose amoxicillin/penicillin G
  ✓ Discontinue MRSA/broad-spectrum cover
  ✓ Continue drainage adequately

Step 4: If ALL tests remain negative:
  ✓ Review pre-analytical factors (prior antibiotics, transport time)
  ✓ Consider repeat sampling or BAL if accessible
  ✓ Consider non-bacterial causes:
       - Viral pleuritis (EBV, influenza)
       - TB (Mantoux, IGRA, pleural biopsy)
       - Malignancy (lymphoma)
       - Autoimmune (lupus pleuritis)
  ✓ Continue empiric antibiotics for full 2-4 week course if clinical picture fits bacterial empyema

Duration of Antibiotics in Culture-Negative Bacterial Empyema

• Minimum 2 weeks IV/oral (or until clinical and drainage resolution)
• Extend to 3-4 weeks if:
  • Necrotizing features on imaging
  • Delayed radiological improvement
  • S. aureus suspected (even without culture confirmation)
  • Immunocompromised host

Age-Specific Organisms in Paediatric Empyema

Key Messages

1. Culture negativity in paediatric empyema is the rule, not the exception - up to 76% of cases are culture negative
2. The main reason is prior antibiotic exposure - organisms are killed but their DNA/antigens persist
3. Pleural fluid PCR identifies a pathogen in 90% of culture-negative cases - request it every time
4. BinaxNOW directly on pleural fluid achieves 100% sensitivity for pneumococcus (2026 data)
5. Inoculate pleural fluid into blood culture bottles - significantly better than plain culture tubes
6. Default working organism is S. pneumoniae serotype 3 (even in vaccinated children) until proved otherwise
7. Do not escalate to broad-spectrum antibiotics based on culture negativity alone - this drives resistance; use molecular diagnostics to de-escalate appropriately

Key References

1. Jacobson et al. Multiplex-qPCR for paediatric pleural empyema. PLoS One, 2024 - [PMID 38917227] - 90% detection by PCR vs. 24% culture
2. Arrieta et al. Parapneumonic Empyema: Etiology in the PCV Era. Pediatr Infect Dis J, 2025 - [PMID 40257269] - 79% pneumococcal diagnoses by PCR only
3. Crawford et al. BinaxNOW in Pleural Fluid for Paediatric Empyema. Clin Pediatrics, 2026 - [PMID 41778409] - 100% sensitivity
4. Sanchez et al. BioFire JI Panel in Paediatric Pleural Infections. J Clin Microbiol, 2025 - [PMID 40892445] - resistance gene detection
5. Murray & Nadel's Textbook of Respiratory Medicine - prior antibiotics and culture yield

Antibiotics for Drug-Resistant Empyema in Children - Complete Guide

Guiding Principle Before Starting

1. MRSA Empyema (Most Dangerous Resistance Pattern)

Empiric therapy (start immediately if MRSA suspected)

Red Book 2021 / IDSA: Vancomycin monotherapy in the first 24h was associated with higher mortality compared to vancomycin combined with clindamycin, linezolid, or ceftaroline in children with MRSA pneumonia complicating influenza. Combination is mandatory for life-threatening disease.

Vancomycin dosing in children:

• 15 mg/kg IV every 6 hours (monitor AUC/MIC with Bayesian estimation - current IDSA/ASHP/PIDS guideline)
• Target AUC/MIC ratio, NOT just trough levels (latest standard)
• Adjust for renal function

Full MRSA Empyema Antibiotic Table (Red Book 2021)

Important notes on CA-MRSA vs HA-MRSA:

• CA-MRSA (community-acquired): Often susceptible to clindamycin, TMP-SMX, tetracyclines, doxycycline - and vancomycin/linezolid
• HA-MRSA (hospital-acquired, older strains): Multidrug resistant - vancomycin remains gold standard

2. Penicillin-Non-Susceptible Pneumococcus (PNSP)

• Ceftriaxone achieves very high pleural fluid concentrations - effective even against many penicillin-resistant strains
• Vancomycin is reserved for cephalosporin-resistant pneumococcus (rare)

3. MDR Gram-Negative Empyema (Hospital-Acquired, Immunocompromised)

Note: Pip-taz pharmacokinetics in children differ from adults - higher clearance rates require more frequent dosing or extended infusions to achieve adequate trough levels. Consider extended 4-hour infusions for serious infections.

4. Anaerobic / Aspiration-Related Empyema

• Rosen's Emergency Medicine confirms: "If lung abscess or empyema is suspected, clindamycin or metronidazole should be added"
• Clindamycin is preferred over metronidazole as monotherapy for anaerobic pleural infection due to better penetration

5. Atypical Organism Empyema (Beta-Lactam Resistant by Nature)

Quick Decision Tool by Severity and Setting

CHILD WITH EMPYEMA - ANTIBIOTIC DECISION

STEP 1: Community vs Hospital-acquired?
│
├── COMMUNITY-ACQUIRED (most children):
│   ├── No MRSA risk factors:
│   │   └── Amoxicillin-clavulanate IV 45-90 mg/kg/day
│   │       OR Cefuroxime 150 mg/kg/day q8h IV
│   │
│   ├── MRSA risk factors* OR severe/toxic child:
│   │   └── Vancomycin 15 mg/kg q6h IV (AUC-guided)
│   │       + Clindamycin or Linezolid (if influenza co-infection)
│   │
│   └── Influenza season + critically ill:
│       └── MANDATORY: Vancomycin + Clindamycin/Linezolid/Ceftaroline
│
├── HOSPITAL-ACQUIRED / ICU / IMMUNOCOMPROMISED:
│   ├── No MDR risk: Pip-Taz 300 mg/kg/day q6-8h IV
│   ├── MDR risk / ESBL: Meropenem 60 mg/kg/day q8h IV
│   ├── Add Vancomycin if MRSA possible
│   └── Carbapenem-resistant: Ceftazidime-avibactam + ID consult
│
└── CULTURE RESULT AVAILABLE:
    ├── Pneumococcus, penicillin-susceptible → Penicillin G or amoxicillin IV
    ├── Pneumococcus, penicillin-resistant → High-dose ceftriaxone IV
    ├── MSSA → Nafcillin or oxacillin or cefazolin (de-escalate from vancomycin!)
    ├── CA-MRSA → Vancomycin; clindamycin if susceptible
    ├── HA-MRSA → Vancomycin ± gentamicin
    ├── GAS (Group A Strep) → Penicillin G + clindamycin
    └── Gram-negatives → targeted per susceptibility

Duration of Therapy

Drugs to Avoid / Pitfalls

Sources

• Red Book 2021 (AAP) [ISBN 9781610025218] - S. aureus treatment table, MRSA empyema/influenza combination data
• Murray & Nadel's Respiratory Medicine - CA-MRSA vancomycin failure data
• St. Louis Children's Hospital ASP Guidelines (updated March 2026) - paediatric empiric dosing
• NCDC National Treatment Guidelines - empyema antibiotic algorithm
• Rosen's Emergency Medicine - anaerobic empyema coverage